MSLN and ovarian cancer: Madeira et al. (2015) included 12 studies (the search was carried out on the MEDLINE, Embase, Cochrane, IBECS, BIOSIS, Web of Science, SCOPUS, and Congress Abstracts databases, as well as on Google Scholar and The British Library, where 111 studies were found) in a meta-analysis to evaluate the mesothelin molecule as a biomarker in ovarian cancer [39,40].